{"id":136837,"date":"2022-11-14T08:47:35","date_gmt":"2022-11-14T13:47:35","guid":{"rendered":"https:\/\/44.250.171.167\/?p=136837"},"modified":"2022-11-14T08:47:36","modified_gmt":"2022-11-14T13:47:36","slug":"aurobindo-pharma-q2fy23-41-fall-in-profits","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-q2fy23-41-fall-in-profits\/","title":{"rendered":"Aurobindo Pharma Q2FY23; 41% Fall in Profits"},"content":{"rendered":"\n

Aurobindo Pharma Ltd.<\/a>\u2018s revenue in Q2FY23 fell 3% to \u20b9 5,739 crores. Consolidated Profit came at \u20b9 409 crores showcasing a 41% fall YoY over the corresponding period.<\/p>\n\n\n\n

\"\"<\/a><\/figure><\/div>\n\n\n\n

In this quarter\u2019s\u00a0press release<\/a>, the reports suggested that the firm has observed a fall in profits due to a rise in expenses.<\/p>\n","protected":false},"excerpt":{"rendered":"

Aurobindo Pharma Ltd.\u2018s revenue in Q2FY23 fell 3% to \u20b9 5,739 crores. Consolidated Profit came at \u20b9 409 crores showcasing a 41% fall YoY over the corresponding period. In this quarter\u2019s\u00a0press release, the reports suggested that the firm has observed a fall in profits due to a rise in expenses.<\/p>\n","protected":false},"author":1885,"featured_media":136838,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392,5747],"tags":[10162],"class_list":["post-136837","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-earnings","category-healthcare-stocks","tag-pharmaceutical"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2022\/11\/Q2FY23-AUROPHARMA.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":168736,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-ltd-q4fy25-0-fall-in-profits\/","url_meta":{"origin":136837,"position":0},"title":"Aurobindo Pharma Ltd Q4FY25; 0% fall in Profits","author":"Divyansh_Kasana","date":"June 10, 2025","format":false,"excerpt":"Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159) Financial Results: Aurobindo Pharma Ltd reported Revenues for Q4FY25 of \u20b98,382.00 Crores up from \u20b97,580.00 Crore year on year, a rise of 10.58%. Total Expenses for\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/I-5.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/I-5.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/I-5.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/I-5.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/I-5.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/I-5.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":167130,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-ltd-q3fy25-10-fall-in-profits\/","url_meta":{"origin":136837,"position":1},"title":"Aurobindo Pharma Ltd Q3FY25; 10% fall in Profits","author":"Divyansh_Kasana","date":"February 28, 2025","format":false,"excerpt":"Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159) Financial Results: Aurobindo Pharma Ltd reported Revenues for Q3FY25 of \u20b97,979.00 Crores up from \u20b97,352.00 Crore year on year, a rise of 8.53%. Total Expenses for\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/F.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/F.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/F.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/F.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/F.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/F.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":133074,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-limited-q1fy23-32-fall-in-profits\/","url_meta":{"origin":136837,"position":2},"title":"Aurobindo Pharma Limited Q1FY23; 32% fall in Profits","author":"Karan_Singh","date":"August 12, 2022","format":false,"excerpt":"Revenue for Q1 FY23 has increased by 9% YoY to \u20b9 6,235.9 crores. Profits have fallen by 32% YoY to \u20b9 520.5 crores because Total Expenses has grown by 17% YoY. In this quarter\u2019s\u00a0results, it was visible that revenue growth could not keep up with the drastic increase in expenses.\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/08\/Q1FY23-AUROPHARMA-IG.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/08\/Q1FY23-AUROPHARMA-IG.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/08\/Q1FY23-AUROPHARMA-IG.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/08\/Q1FY23-AUROPHARMA-IG.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/08\/Q1FY23-AUROPHARMA-IG.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":142550,"url":"https:\/\/alphastreet.com\/india\/earnings-aurobindo-pharma-ltd-nseauropharma-q3fy23-results-out-total-income-rise-7-yoy\/","url_meta":{"origin":136837,"position":3},"title":"Earnings | Aurobindo Pharma Ltd. (NSE:AUROPHARMA): Q3FY23 Results Out; Total Income rise 7% YoY","author":"Divyansh_Kasana","date":"February 22, 2023","format":false,"excerpt":"Aurobindo Pharma Ltd. (NSE:AUROPHARMA) is a global pharmaceutical company headquartered in India. The company produces and sells a wide range of generic pharmaceutical products and active pharmaceutical ingredients (APIs) in over 150 countries. Aurobindo Pharma's portfolio includes antibiotics, anti-retrovirals, anti-inflammatory drugs, cardiovascular drugs, and more. The company operates manufacturing facilities\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":165862,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-ltd-q2fy25-9-rise-in-profits\/","url_meta":{"origin":136837,"position":4},"title":"Aurobindo Pharma Ltd Q2FY25; 9% rise in Profits","author":"Divyansh_Kasana","date":"December 2, 2024","format":false,"excerpt":"Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159) Financial Results: Aurobindo Pharma Ltd reported Revenues for Q2FY25 of \u20b97,796.00 Crores up from \u20b97,219.00 Crore year on year, a rise of 7.99%. Total Expenses for\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/BK.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/BK.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/BK.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/BK.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/BK.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/BK.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":125403,"url":"https:\/\/alphastreet.com\/india\/earnings-aurobindo-pharma-results-in-q2-2022\/","url_meta":{"origin":136837,"position":5},"title":"Earnings: Aurobindo Pharma results in Q2 2022","author":"Nishadkishore","date":"November 8, 2021","format":false,"excerpt":"Aurobindo Pharma (NSE: AUROPHARMA) reported its second-quarter 2022 earnings results today. The company had a consolidated net profit of \u20b9696.71 crores with a decline of 14% compared to the previous year. Consolidated total revenue from operations during the period was at \u20b95,941.92 crores compared to \u20b96,483.44 crores for the same\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/136837","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1885"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=136837"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/136837\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/136838"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=136837"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=136837"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=136837"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}